A David Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2919793/publications.pdf Version: 2024-02-01

		1612	2446
352	43,516	105	197
papers	citations	h-index	g-index
361	361	361	30592
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The dihydrofolate reductase 19-bp deletion modifies the beneficial effect of B-vitamin therapy in mild cognitive impairment: pooled study of two randomized placebo-controlled trials. Human Molecular Genetics, 2022, 31, 1151-1158.	1.4	4
2	The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?. Alzheimer's and Dementia, 2022, 18, 507-512.	0.4	7
3	Vitamin B-12. Advances in Nutrition, 2022, 13, 2061-2063.	2.9	5
4	Association of life course adiposity with risk of incident dementia: a prospective cohort study of 322,336 participants. Molecular Psychiatry, 2022, 27, 3385-3395.	4.1	11
5	Omega-3 Supplementation for the Prevention of Cognitive Decline in Older Adults: Does It Depend on Homocysteine Levels?. Journal of Nutrition, Health and Aging, 2022, 26, 615-620.	1.5	4
6	ï‰-3 fatty acids and their interactions. American Journal of Clinical Nutrition, 2021, 113, 775-778.	2.2	5
7	Anti-amyloid trials raise scientific and ethical questions. BMJ, The, 2021, 372, n805.	3.0	6
8	Homocysteine – from disease biomarker to disease prevention. Journal of Internal Medicine, 2021, 290, 826-854.	2.7	109
9	Paraoxonase 1, B Vitamins Supplementation, and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 81, 1211-1229.	1.2	20
10	Antiâ€ <i>N</i> â€homocysteineâ€protein autoantibodies are associated with impaired cognition. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12159.	1.8	8
11	B Vitamins Prevent Iron-Associated Brain Atrophy and Domain-Specific Effects of Iron, Copper, Aluminum, and Silicon on Cognition in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 84, 1039-1055.	1.2	10
12	Effectiveness of B Vitamins and Their Interactions with Aspirin in Improving Cognitive Functioning in Older People with Mild Cognitive Impairment: Pooled Post-Hoc Analyses of Two Randomized Trials. Journal of Nutrition, Health and Aging, 2021, 25, 1154-1160.	1.5	9
13	Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An inâ€depth exploration of seven established risk factors. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12202.	1.8	12
14	Glutathione Serum Levels and Rate of Multimorbidity Development in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1089-1094.	1.7	20
15	A Machine Learning Approach to Identify a Circulating MicroRNA Signature for Alzheimer Disease. journal of applied laboratory medicine, The, 2020, 5, 15-28.	0.6	17
16	Vitamin C—An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. Nutrients, 2020, 12, 3760.	1.7	123
17	Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition. Nutrients, 2020, 12, 2555.	1.7	100
18	Association of Homocysteine, Methionine, and <i>MTHFR</i> 677C>T Polymorphism With Rate of Cardiovascular Multimorbidity Development in Older Adults in Sweden. JAMA Network Open, 2020, 3, e205316.	2.8	14

#	Article	IF	CITATIONS
19	Nutrition and the ageing brain: Moving towards clinical applications. Ageing Research Reviews, 2020, 62, 101079.	5.0	56
20	Association of Methionine to Homocysteine Status With Brain Magnetic Resonance Imaging Measures and Risk of Dementia. JAMA Psychiatry, 2019, 76, 1198.	6.0	36
21	Evaluation of (â^)-epicatechin metabolites as recovery biomarker of dietary flavan-3-ol intake. Scientific Reports, 2019, 9, 13108.	1.6	21
22	Combined Anti-inflammatory and Neuroprotective Treatments Have the Potential to Impact Disease Phenotypes in Cln3â^'/â^' Mice. Frontiers in Neurology, 2019, 10, 963.	1.1	13
23	Dietary Supplements for Brain Health. JAMA - Journal of the American Medical Association, 2019, 321, 2467.	3.8	0
24	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk. Journal of Alzheimer's Disease, 2019, 68, 1535-1547.	1.2	11
25	Imaging of changes in copper trafficking and redistribution in a mouse model of Niemann-Pick C disease using positron emission tomography. BioMetals, 2019, 32, 293-306.	1.8	7
26	Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study. Journal of Alzheimer's Disease, 2019, 69, 189-197.	1.2	44
27	Nâ€homocysteinylation of tau and MAP1 is increased in autopsy specimens of Alzheimer's disease and vascular dementia. Journal of Pathology, 2019, 248, 291-303.	2.1	35
28	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
29	Interaction of nutrition and genetics via DNMT3L-mediated DNA methylation determines cognitive decline. Neurobiology of Aging, 2019, 78, 64-73.	1.5	7
30	The kynurenine pathway and cognitive performance in community-dwelling older adults. The Hordaland Health Study. Brain, Behavior, and Immunity, 2019, 75, 155-162.	2.0	46
31	Homocysteine and Dementia: An International Consensus Statement. Journal of Alzheimer's Disease, 2018, 62, 561-570.	1.2	242
32	Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review. Journal of Nutrition, 2018, 148, 1995S-2027S.	1.3	166
33	Maternal and infant vitamin B12 status and development. Pediatric Research, 2018, 84, 591-592.	1.1	0
34	Vitamin B12. Advances in Food and Nutrition Research, 2018, 83, 215-279.	1.5	105
35	Dementia research priorities—2. Lancet Neurology, The, 2017, 16, 181-182.	4.9	8
36	The soluble transcobalamin receptor (sCD320) in relation to Alzheimer's disease and cognitive scores. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 332-337.	0.6	0

#	Article	IF	CITATIONS
37	Folic Acid for the Prevention of Neural Tube Defects. JAMA Pediatrics, 2017, 171, 710.	3.3	2
38	Kynurenine Pathway Metabolites in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 495-504.	1.2	99
39	Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. Neurobiology of Aging, 2017, 49, 215.e1-215.e8.	1.5	21
40	Elevated homocysteine and N-methyl-d-aspartate-receptor antibodies as a cause of behavioural and cognitive decline in 22q11.2 deletion syndrome. Oxford Medical Case Reports, 2017, 2017, omx076.	0.2	4
41	DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITION. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-2.	1.5	10
42	Differential response of the liver to bile acid treatment in a mouse model of Niemann-Pick disease type C. Wellcome Open Research, 2017, 2, 76.	0.9	2
43	Association of Vitamin B ₁₂ , Folate, and Sulfur Amino Acids With Brain Magnetic Resonance Imaging Measures in Older Adults. JAMA Psychiatry, 2016, 73, 606.	6.0	78
44	Bâ€vitamins are potentially a costâ€effective population health strategy to tackle dementia: Too good to be true?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 156-161.	1.8	14
45	Cognitive decline in the elderly after surgery and anaesthesia: results from the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Anaesthesia, 2016, 71, 1144-1152.	1.8	55
46	Evidence-based prevention and treatment of dementia. Lancet Neurology, The, 2016, 15, 1005-1006.	4.9	0
47	Homocysteine, B Vitamins, and Cognitive Impairment. Annual Review of Nutrition, 2016, 36, 211-239.	4.3	361
48	Omega-3 Fatty Acid Status Enhances theÂPrevention of Cognitive Decline byÂBÂVitamins in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 50, 547-557.	1.2	117
49	ABCA7 p.C215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	1.5	37
50	Hippocampus as a mediator of the role of vitamin B-12 in memory. American Journal of Clinical Nutrition, 2016, 103, 959-960.	2.2	9
51	Decision on folic acid fortification in Europe must consider both risks and benefits. BMJ, The, 2016, 352, i734.	3.0	12
52	Screening exons 16 and 17 of the amyloid precursor protein gene in sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 39, 220.e1-220.e7.	1.5	12
53	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
54	The Effects of Two Polymorphisms on p21cip1 Function and Their Association with Alzheimer's Disease in a Population of European Descent. PLoS ONE, 2015, 10, e0114050.	1.1	16

#	Article	IF	CITATIONS
55	Blood type gene locus has no influence on ACE association with Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1767.e1-1767.e2.	1.5	2
56	Homocysteine lowering, B vitamins, and cognitive aging. American Journal of Clinical Nutrition, 2015, 101, 415-416.	2.2	17
57	Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. American Journal of Clinical Nutrition, 2015, 102, 215-221.	2.2	150
58	Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort. Journal of Alzheimer's Disease, 2015, 44, 525-539.	1.2	69
59	Cerebral Amyloid Angiopathy, Subcortical White Matter Disease and Dementia: Literature Review and Study in <scp>OPTIMA</scp> . Brain Pathology, 2015, 25, 51-62.	2.1	47
60	High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid. PLoS ONE, 2015, 10, e0135365.	1.1	57
61	Interactions between plasma concentrations of folate and markers of vitamin B ₁₂ status with cognitive performance in elderly people not exposed to folic acid fortification: the Hordaland Health Study. British Journal of Nutrition, 2014, 111, 1085-1095.	1.2	41
62	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	3.9	75
63	Cerebral Subcortical Small Vessel Disease in Subjects With Pathologically Confirmed Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2014, 28, 30-35.	0.6	36
64	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature, 2014, 505, 550-554.	13.7	425
65	The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project. European Journal of Human Genetics, 2014, 22, 216-220.	1.4	35
66	Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluid. International Journal of Molecular Epidemiology and Genetics, 2014, 5, 53-70.	0.4	10
67	Discovery by the Epistasis Project of an epistatic interaction between the CSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1309.e1-1309.e7.	1.5	29
68	Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 3.	2.4	55
69	The impact of early life factors on cognitive function in old age: The Hordaland Health Study (HUSK). BMC Psychology, 2013, 1, 16.	0.9	8
70	Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9523-9528.	3.3	422
71	Structural and functional bases of visuospatial associative memory in older adults. Neurobiology of Aging, 2013, 34, 961-972.	1.5	15
72	Cognitive Function in an Elderly Population. Psychosomatic Medicine, 2013, 75, 20-29.	1.3	57

#	Article	IF	CITATIONS
73	Human hippocampal energy metabolism is impaired during cognitive activity in a lipid infusion model of insulin resistance. Brain and Behavior, 2013, 3, 134-144.	1.0	34
74	Dementia (Including Alzheimer's Disease) can be Prevented: Statement Supported by International Experts. Journal of Alzheimer's Disease, 2013, 38, 699-703.	1.2	55
75	Cysteine and obesity. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 49-57.	1.3	86
76	The Role of Variation at AÎ ² PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	1.2	53
77	Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiology of Aging, 2012, 33, 202.e1-202.e13.	1.5	51
78	Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiology of Aging, 2012, 33, 1849.e5-1849.e18.	1.5	43
79	The association of fasting plasma sulfur-containing compounds with BMI, serum lipids and apolipoproteins. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 1031-1038.	1.1	80
80	Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2012, 28, 625-636.	1.2	50
81	Cognitive and clinical outcomes of homocysteineâ€lowering Bâ€vitamin treatment in mild cognitive impairment: a randomized controlled trial. International Journal of Geriatric Psychiatry, 2012, 27, 592-600.	1.3	345
82	Interaction of insulin and PPAR-α genes in Alzheimer's disease: the Epistasis Project. Journal of Neural Transmission, 2012, 119, 473-479.	1.4	20
83	Do we need to reconsider the desirable blood level of vitamin B12?. Journal of Internal Medicine, 2012, 271, 179-182.	2.7	50
84	Cysteine and Obesity. Obesity, 2012, 20, 473-481.	1.5	59
85	Dietary cystine level affects metabolic rate and glycaemic control in adult mice. Journal of Nutritional Biochemistry, 2012, 23, 332-340.	1.9	54
86	Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: a pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathology and Applied Neurobiology, 2012, 38, 337-343.	1.8	113
87	Vitamin B-12 Status during Pregnancy and Child's IQ at Age 8: A Mendelian Randomization Study in the Avon Longitudinal Study of Parents and Children. PLoS ONE, 2012, 7, e51084.	1.1	30
88	Interactions between PPAR-α and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 39-47.	0.4	13
89	Cysteine supplementation reverses methionine restriction effects on rat adiposity: significance of stearoyl-coenzyme A desaturase. Journal of Lipid Research, 2011, 52, 104-112.	2.0	133
90	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2011, 1, 31-42.	0.6	35

#	Article	IF	CITATIONS
91	Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. Alzheimer's Research and Therapy, 2011, 3, 5.	3.0	22
92	Upregulation of AMPA receptor GluR2 (GluA2) subunits in subcortical ischemic vascular dementia is repressed in the presence of Alzheimer's disease. Neurochemistry International, 2011, 58, 820-825.	1.9	14
93	The vitamin D receptor gene is associated with Alzheimer's disease. Neuroscience Letters, 2011, 504, 79-82.	1.0	76
94	A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 587-597.	1.2	33
95	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
96	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.1	17
97	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 316-27.	0.4	9
98	Homocysteine as a predictor of cognitive decline in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 82-90.	1.3	91
99	Genome wide profiling of altered gene expression in the neocortex of Alzheimer's disease. Journal of Neuroscience Research, 2010, 88, 1157-1169.	1.3	108
100	Concordance of Gastrointestinal Tract Colonization and Subsequent Bloodstream Infections With Gram-negative Bacilli in Very Low Birth Weight Infants in the Neonatal Intensive Care Unit. Pediatric Infectious Disease Journal, 2010, 29, 831-835.	1.1	88
101	Cognitive performance among the elderly in relation to the intake of plant foods. The Hordaland Health Study. British Journal of Nutrition, 2010, 104, 1190-1201.	1.2	84
102	Universal screening for meticillin-resistant Staphylococcus aureus: interim results from the NHS Scotland pathfinder project. Journal of Hospital Infection, 2010, 74, 35-41.	1.4	40
103	Sulfur amino acids in methionine-restricted rats: Hyperhomocysteinemia. Nutrition, 2010, 26, 1201-1204.	1.1	83
104	The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Medical Genetics, 2010, 11, 162.	2.1	50
105	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	1.1	347
106	Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2833-2838.	1.1	20
107	Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aß, and Alzheimer's Disease. PLoS ONE, 2010, 5, e8764.	1.1	48
108	Folic acid nutrition: what about the little children?. American Journal of Clinical Nutrition, 2010, 91, 1408-1409.	2.2	8

#	Article	IF	CITATIONS
109	Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1632-1642.	1.1	142
110	Association of the aromatase gene with Alzheimer's disease in women. Neuroscience Letters, 2010, 468, 202-206.	1.0	34
111	Genetic variation in homocysteine metabolism, cognition, and white matter lesions. Neurobiology of Aging, 2010, 31, 2020-2022.	1.5	30
112	Why are drug trials in Alzheimer's disease failing?. Lancet, The, 2010, 376, 1466.	6.3	14
113	Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. PLoS ONE, 2010, 5, e12244.	1.1	612
114	Blood Pressure, Dementia and Alzheimer's Disease: The OPTIMA Longitudinal Study. Dementia and Geriatric Cognitive Disorders, 2009, 28, 70-74.	0.7	50
115	Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 667-670.	0.9	70
116	Determinants of Plasma Methylmalonic Acid in a Large Population: Implications for Assessment of Vitamin B12 Status. Clinical Chemistry, 2009, 55, 2198-2206.	1.5	109
117	Dietary sources of vitamin B-12 and their association with plasma vitamin B-12 concentrations in the general population: the Hordaland Homocysteine Study. American Journal of Clinical Nutrition, 2009, 89, 1078-1087.	2.2	127
118	Intake of Flavonoid-Rich Wine, Tea, and Chocolate by Elderly Men and Women Is Associated with Better Cognitive Test Performance. Journal of Nutrition, 2009, 139, 120-127.	1.3	212
119	Predicting the time of conversion to MCI in the elderly. Neurology, 2009, 73, 1436-1442.	1.5	61
120	Vitamin B-12 and cognition in the elderly. American Journal of Clinical Nutrition, 2009, 89, 707S-711S.	2.2	110
121	Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiology of Disease, 2009, 36, 242-251.	2.1	132
122	The synergy factor: a statistic to measure interactions in complex diseases. BMC Research Notes, 2009, 2, 105.	0.6	96
123	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	9.4	2,697
124	Association study of MICA and MICB in Alzheimer's disease. Tissue Antigens, 2009, 74, 241-243.	1.0	3
125	Cysteine, homocysteine and bone mineral density: A role for body composition?. Bone, 2009, 44, 954-958.	1.4	23
126	Epistasis in sporadic Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1333-1349.	1.5	111

#	Article	IF	CITATIONS
127	PSEN1 polymorphisms alter the rate of cognitive decline in sporadic Alzheimer's disease patients. Neurobiology of Aging, 2009, 30, 1992-1999.	1.5	17
128	Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. Journal of Neuroinflammation, 2009, 6, 22.	3.1	46
129	Plasma vitamin B12 status and cerebral white-matter lesions. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 149-157.	0.9	106
130	The Association of Plasma Cysteine and γâ€Glutamyltransferase With BMI and Obesity. Obesity, 2009, 17, 1435-1440.	1.5	58
131	Hydrophobic Protein that Copurifies with Human Brain Acetylcholinesterase. Journal of Neurochemistry, 2008, 74, 2146-2153.	2.1	30
132	Polymorphisms in the catecholâ€ <i>O</i> â€methyltransferase (COMT) gene influence plasma total homocysteine levels. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 996-999.	1.1	45
133	Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neuroscience Letters, 2008, 442, 297-299.	1.0	10
134	A SNP in the ACT gene associated with astrocytosis and rapid cognitive decline in AD. Neurobiology of Aging, 2008, 29, 1167-1176.	1.5	13
135	Vitamin B ₁₂ status and rate of brain volume loss in community-dwelling elderly. Neurology, 2008, 71, 826-832.	1.5	174
136	The Worldwide Challenge of the Dementias: A Role for B Vitamins and Homocysteine?. Food and Nutrition Bulletin, 2008, 29, S143-S172.	0.5	200
137	Are we ready for mandatory fortification with vitamin B-12?. American Journal of Clinical Nutrition, 2008, 88, 253-254.	2.2	23
138	Is folic acid good for everyone?. American Journal of Clinical Nutrition, 2008, 87, 517-533.	2.2	502
139	Reply to E Baggott and SL Morgan. American Journal of Clinical Nutrition, 2008, 88, 480.	2.2	1
140	Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. American Journal of Clinical Nutrition, 2007, 86, 1470-1478.	2.2	135
141	Plasma folate concentration and cognitive performance: Rotterdam Scan Study. American Journal of Clinical Nutrition, 2007, 86, 728-734.	2.2	70
142	Folic acid fortification: the good, the bad, and the puzzle of vitamin B-12. American Journal of Clinical Nutrition, 2007, 85, 3-5.	2.2	94
143	Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study. American Journal of Clinical Nutrition, 2007, 86, 514-521.	2.2	33
144	Reply to RJ Berry et al. American Journal of Clinical Nutrition, 2007, 86, 268-269.	2.2	1

9

#	Article	IF	CITATIONS
145	Iron genes, iron load and risk of Alzheimer's disease. Journal of Medical Genetics, 2006, 43, e52-e52.	1.5	43
146	Replication of the association of HLA-B7 with Alzheimer's disease: a role for homozygosity?. Journal of Neuroinflammation, 2006, 3, 33.	3.1	16
147	Peripheral reductive capacity is associated with cognitive performance and survival in Alzheimer's disease. Journal of Neuroinflammation, 2006, 3, 4.	3.1	12
148	The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease. Journal of Nutrition, 2006, 136, 1731S-1740S.	1.3	404
149	Hippocampal atrophy in Alzheimer disease: Age matters. Neurology, 2006, 67, 728-728.	1.5	0
150	Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 85-88.	0.9	87
151	Prevention of Dementia: A Role for B Vitamins?. Nutrition and Health, 2006, 18, 225-226.	0.6	11
152	Apolipoprotein E Â4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 902-908.	0.9	43
153	The association between depression, anxiety, and cognitive function in the elderly general population—the Hordaland Health Study. International Journal of Geriatric Psychiatry, 2005, 20, 989-997.	1.3	74
154	Plasma total homocysteine and memory in the elderly: The Hordaland Homocysteine study. Annals of Neurology, 2005, 58, 847-857.	2.8	147
155	Medial Temporal Lobe Atrophy, Apolipoprotein Genotype, and Plasma Homocysteine in Sri Lankan Patients with Alzheimer's Disease. Experimental Aging Research, 2005, 31, 345-354.	0.6	13
156	Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 640-643.	0.9	85
157	Large Meta-Analysis Establishes the ACE Insertion-Deletion Polymorphism as a Marker of Alzheimer's Disease. American Journal of Epidemiology, 2005, 162, 305-317.	1.6	190
158	Pathological Validation of a CT-Based Scale for Subcortical Vascular Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 61-66.	0.7	12
159	Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Experimental Neurology, 2005, 193, 420-426.	2.0	25
160	Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology, 2004, 62, 1967-1971.	1.5	124
161	Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. Journal of Medical Genetics, 2004, 41, 261-265.	1.5	107
162	Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion. Clinical Chemistry, 2004, 50, 3-32.	1.5	913

#	Article	IF	CITATIONS
163	Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology, 2004, 29, 405-421.	1.3	105
164	Low free testosterone is an independent risk factor for Alzheimer's disease. Experimental Gerontology, 2004, 39, 1633-1639.	1.2	182
165	The CT-based radial width of the temporal horn: pathological validation in AD without cerebrovascular disease. International Journal of Geriatric Psychiatry, 2004, 19, 570-574.	1.3	20
166	Association between subcortical vascular disease on CT and neuropathological findings. International Journal of Geriatric Psychiatry, 2004, 19, 690-695.	1.3	24
167	Prevalence of dementia in a semi-urban population in Sri Lanka: report from a regional survey. International Journal of Geriatric Psychiatry, 2003, 18, 711-715.	1.3	69
168	Association of the androgen receptor CAG repeat polymorphism with Alzheimer's disease in men. Neuroscience Letters, 2003, 340, 87-90.	1.0	43
169	Measuring serum oestradiol in women with Alzheimer's disease: the importance of the sensitivity of the assay method. European Journal of Endocrinology, 2003, 148, 67-72.	1.9	35
170	Low vitamin B-12 status in confirmed Alzheimer's disease as revealed by serum holotranscobalamin. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 959-961.	0.9	66
171	The Validity and Reliability of 6 Sets of Clinical Criteria to Classify Alzheimer's Disease and Vascular Dementia in Cases Confirmed Post-Mortem: Added Value of a Decision Tree Approach. Dementia and Geriatric Cognitive Disorders, 2003, 16, 170-180.	0.7	71
172	Imaging the progression of Alzheimer pathology through the brain. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4135-4137.	3.3	185
173	Plasma Homocysteine Levels, Cerebrovascular Risk Factors, and Cerebral White Matter Changes (Leukoaraiosis) in Patients With Alzheimer Disease. Archives of Neurology, 2002, 59, 787.	4.9	165
174	Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain, 2002, 125, 2332-2341.	3.7	115
175	Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer's disease. British Journal of Radiology, 2002, 75, 506-513.	1.0	63
176	Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain, 2002, 125, 1772-1781.	3.7	177
177	Homocysteine, B vitamins, and cognitive deficit in the elderly. American Journal of Clinical Nutrition, 2002, 75, 785-786.	2.2	68
178	Human homologue of a gene mutated in the slow Wallerian degeneration (C57BL/ Wld s) mouse. Gene, 2002, 284, 23-29.	1.0	21
179	Effect of Bilateral 6-Hydroxydopamine Lesions of the Medial Forebrain Bundle on Reaction Time. Neuropsychopharmacology, 2002, 26, 756-764.	2.8	35
180	Apolipoprotein E ?4 and testosterone interact in the risk of Alzheimer's disease in men. International Journal of Geriatric Psychiatry, 2002, 17, 938-940.	1.3	74

#	Article	IF	CITATIONS
181	Total Plasma Homocysteine, Age, Systolic Blood Pressure, and Cognitive Performance in Older People. Journal of the American Geriatrics Society, 2002, 50, 2014-2018.	1.3	124
182	HLA class I, II & III genes in confirmed late-onset Alzheimer's disease. Neurobiology of Aging, 2001, 22, 71-77.	1.5	28
183	Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience, 2001, 108, 541-554.	1.1	57
184	Deafferentation of the hippocampus results in the induction of AT8 positive â€~granules' in the rat. Neuroscience Letters, 2001, 301, 5-8.	1.0	6
185	Age-Related Impairment of Synaptic Transmission But Normal Long-Term Potentiation in Transgenic Mice that Overexpress the Human APP695SWE Mutant Form of Amyloid Precursor Protein. Journal of Neuroscience, 2001, 21, 4691-4698.	1.7	193
186	SPECT perfusion imaging in the diagnosis of Alzheimer's disease. Neurology, 2001, 56, 950-956.	1.5	232
187	Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 739-743.	0.9	124
188	Serum total testosterone is lower in men with Alzheimer's disease. Neuroendocrinology Letters, 2001, 22, 163-8.	0.2	104
189	Plasma Total Homocysteine and Cognitive Performance in a Volunteer Elderly Population. Annals of the New York Academy of Sciences, 2000, 903, 407-410.	1.8	91
190	Leukoaraiosis at Presentation and Disease Progression during Follow-up in Histologically Confirmed Cases of Dementia. Annals of the New York Academy of Sciences, 2000, 903, 497-500.	1.8	22
191	Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Human Genetics, 2000, 106, 447-452.	1.8	48
192	Evaluation of Novel Assays in Clinical Chemistry: Quantification of Plasma Total Homocysteine. Clinical Chemistry, 2000, 46, 1150-1156.	1.5	93
193	Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Human Molecular Genetics, 2000, 9, 2837-2844.	1.4	147
194	Diagnosing Dementia: Interrater Reliability Assessment and Accuracy of the NINCDS/ADRDA Criteria versus CERAD Histopathological Criteria for Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2000, 11, 107-113.	0.7	43
195	Apolipoprotein E epsilon 2 may be a risk factor for sporadic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 404-405.	0.9	28
196	Hyperhomocysteinaemia in Alzheimer's disease and expression of cell cycle markers in the brain. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 565-566.	0.9	19
197	The Progression of Alzheimer's Disease from Limbic Regions to the Neocortex: Clinical, Radiological and Pathological Relationships. Dementia and Geriatric Cognitive Disorders, 1999, 10, 115-120.	0.7	71
198	Species-dependent effects of adenosine receptor agonists on contractile responses of vas deferens to ATP. Autonomic and Autacoid Pharmacology, 1999, 19, 181-184.	0.7	0

#	Article	lF	CITATIONS
199	Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet, The, 1999, 354, 919-920.	6.3	457
200	Relationship between Clinical and Radiological Diagnostic Criteria for Alzheimer's Disease and the Extent of Neuropathology as Reflected by â€~Stages': A Prospective Study. Dementia and Geriatric Cognitive Disorders, 1999, 10, 109-114.	0.7	43
201	Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. Journal of Neural Transmission, 1998, 105, 39-52.	1.4	36
202	Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet, The, 1998, 352, 1590-1593.	6.3	41
203	Discussion. Neuroscience, 1998, 87, 731-739.	1.1	148
204	Folate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease. Archives of Neurology, 1998, 55, 1449.	4.9	1,333
205	Longitudinal Study of Inflammatory Factors in Serum, Cerebrospinal Fluid, and Brain Tissue in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 215-227.	0.6	168
206	Comparison of Pathological Diagnostic Criteria for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 182-189.	0.6	37
207	Accuracy of Clinical Operational Diagnostic Criteria for Alzheimer's Disease in Relation to Different Pathological Diagnostic Protocols. Dementia and Geriatric Cognitive Disorders, 1998, 9, 219-226.	0.7	82
208	Age Influences the Synergy between Butyrylcholinesterase K Variant and Apolipoprotein E ε4 in Late-Onset Alzheimer's Disease. , 1998, , 159-166.		2
209	The Effects of Additional Pathology on the Cognitive Deficit in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1997, 56, 165-170.	0.9	196
210	Synergy Between the Genes for Butyrylcholinesterase K Variant and Apolipoprotein E4 in Late-Onset Confirmed Alzheimer's Disease. Human Molecular Genetics, 1997, 6, 1933-1936.	1.4	208
211	COMPETITION OF ADENINE NUCLEOTIDES FOR A I,3-[3H]-DIPROPYL-8-CYCLOPENTYLXANTHINE BINDING SITE IN RAT VAS DEFERENS. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 492-497.	0.9	14
212	Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathologica, 1997, 93, 294-300.	3.9	210
213	Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathologica, 1997, 94, 6-15.	3.9	297
214	The substantia nigra as a site of synaptic integration of functionally diverse information arising from the ventral pallidum and the globus pallidus in the rat. Neuroscience, 1996, 75, 5-12.	1.1	86
215	Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet, The, 1996, 348, 483-484.	6.3	30
216	Neuroimaging and early Alzheimer's disease. Lancet, The, 1996, 348, 829-830.	6.3	11

#	Article	IF	CITATIONS
217	Hippocampal Pathology Reflects Memory Deficit and Brain Imaging Measurements in Alzheimers Disease: Clinicopathologic Correlations Using Three Sets of Pathologic Diagnostic Criteria. Dementia and Geriatric Cognitive Disorders, 1996, 7, 76-81.	0.7	53
218	Use of structural imaging to study the progression of Alzheimer's disease. British Medical Bulletin, 1996, 52, 575-586.	2.7	67
219	Amygdala input to medial prefrontal cortex (mPFC) in the rat: A light and electron microscope study. Brain Research, 1996, 720, 211-219.	1.1	159
220	Synaptic Connections Between Spiny Neurons of the Direct and Indirect Pathways in the Neostriatum of the Rat: Evidence from Dopamine Receptor and Neuropeptide Immunostaining. European Journal of Neuroscience, 1996, 8, 861-869.	1.2	124
221	Relative Roles of Plaques and Tangles in the Dementia of Alzheimer's Disease: Correlations Using Three Sets of Neuropathological Criteria. Dementia and Geriatric Cognitive Disorders, 1995, 6, 21-31.	0.7	156
222	Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience, 1995, 69, 757-761.	1.1	229
223	Hippocampal atrophy and cognitive impairment. Lancet, The, 1995, 345, 992.	6.3	4
224	Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy. Neuroscience, 1995, 65, 709-730.	1.1	497
225	Radiological detection of proven Alzheimer's disease during life using CT evidence of minimum medial temporal lobe thickness. , 1995, , 197-199.		1
226	Monosynaptic innervation of facial motoneurones by neurones of the parvicellular reticular formation. Experimental Brain Research, 1994, 101, 427-38.	0.7	31
227	Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet, The, 1994, 343, 829-830.	6.3	208
228	The effects of chronic administration of ceronapril on the partial reinforcement extinction effect and latent inhibition in rats. Behavioural Pharmacology, 1994, 5, 306-314.	0.8	8
229	Monosynaptic innervation of trigeminal motor neurones involved in mastication by neurones of the parvicellular reticular formation. Journal of Comparative Neurology, 1993, 336, 53-65.	0.9	60
230	Monosynaptic projections from the rostral ventrolateral medulla oblongata to identified sympathetic preganglionic neurons. Neuroscience, 1993, 54, 729-743.	1.1	121
231	A monosynaptic pathway from an identified vasomotor centre in the medial prefrontal cortex to an autonomic area in the thoracic spinal cord. Neuroscience, 1993, 54, 719-728.	1.1	93
232	Measurement of medial temporal lobe atrophy in diagnosis of Alzheimer's disease. Lancet, The, 1993, 341, 125-126.	6.3	44
233	Chapter 5 Convergence of synaptic terminals from the striatum and the globus pallidus onto single neurones in the substantia nigra and the entopeduncular nucleus. Progress in Brain Research, 1993, 99, 73-88.	0.9	42
234	Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 190-194.	0.9	136

#	Article	IF	CITATIONS
235	Synaptic organization of gabaergic inputs from the striatum and the globus pallidus onto neurons in the substantia nigra and retrorubral field which project to the medullary reticular formation. Neuroscience, 1992, 50, 531-549.	1.1	119
236	Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet, The, 1992, 340, 1179-1183.	6.3	260
237	A neuroleptic-like effect of ceronapril on latent inhibition. Neuroscience, 1992, 49, 307-315.	1.1	14
238	Maxwell's role. Nature, 1992, 355, 490-490.	13.7	1
239	Cost of brain disorders. Nature, 1992, 358, 184-184.	13.7	0
240	Anomalous molecular form of acetylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease. Lancet, The, 1991, 337, 447-450.	6.3	66
241	Anomalous acetylcholinesterase in lumbar CSF in Alzheimer's disease. Lancet, The, 1991, 338, 1538.	6.3	9
242	GABA-like immunoreactivity in different cellular populations of cerebellar cortex of rats before and after treatment with amino-oxyacetic acid. Brain Research, 1991, 543, 277-286.	1.1	16
243	Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell, 1991, 65, 91-104.	13.5	817
244	The neuropsychology of schizophrenia. Behavioral and Brain Sciences, 1991, 14, 1-20.	0.4	1,135
245	Descending Projections from the Substantia Nigra and Retrorubral Field to the Medullary and Pontomedullary Reticular Formation. European Journal of Neuroscience, 1991, 3, 260-273.	1.2	72
246	Coexistence of GABA and glutamate in mossy fiber terminals of the primate hippocampus: An ultrastructural study. Journal of Comparative Neurology, 1991, 303, 177-192.	0.9	179
247	Sites of [3H]taurine Uptake in the Rat Substantia Nigra in Relation to the Release of Taurine from the Striatonigral Pathway. European Journal of Neuroscience, 1990, 2, 50-61.	1.2	37
248	Purification and characterization of bovine brain type I phosphatidylinositol kinase. FEBS Journal, 1990, 191, 761-767.	0.2	132
249	Electron microscopic evidence of a monosynaptic pathway between cells in the caudal raph nuclei and sympathetic preganglionic neurons in the rat spinal cord. Experimental Brain Research, 1990, 79, 589-602.	0.7	112
250	The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends in Neurosciences, 1990, 13, 259-265.	4.2	958
251	Secretion of acetylcholinesterase and butyrylcholinesterase from the guineaâ€pig isolated ileum. British Journal of Pharmacology, 1989, 97, 490-498.	2.7	19
252	Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. Journal of Chemical Neuroanatomy, 1989, 2, 285-98.	1.0	214

#	Article	IF	CITATIONS
253	Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. Journal of Comparative Neurology, 1988, 267, 455-471.	0.9	298
254	GABA-immunoreactive synaptic boutons in the rat basal forebrain: Comparison of neurons that project to the neocortex with pallidosubthalamic neurons. Journal of Comparative Neurology, 1988, 273, 263-282.	0.9	127
255	A simple and rapid method for the production of cholera B-chain coupled to horseradish peroxidase for neuronal tracing. Journal of Neuroscience Methods, 1988, 22, 189-194.	1.3	38
256	Preganglionic sympathetic neurones innervating the rat adrenal medulla: immunocytochemical evidence of synaptic input from nerve terminals containing substance P, GABA or 5-hydroxytryptamine. Journal of the Autonomic Nervous System, 1988, 24, 97-122.	1.9	158
257	CHOLINESTERASE ACTIVITIES IN CEREBROSPINAL FLUID OF PATIENTS WITH SENILE DEMENTIA OF ALZHEIMER TYPE. Brain, 1987, 110, 1309-1322.	3.7	59
258	Spontaneous and carbachol-evoked in vivo secretion of acetylcholinesterase from the hippocampus of the rat. Neurochemistry International, 1987, 11, 397-406.	1.9	17
259	Synaptic input and local output of dopaminergic neurons in grafts that functionally reinnervate the host neostriatum. Experimental Brain Research, 1987, 68, 131-46.	0.7	135
260	Uptake, Localization and Release of Taurine in the Rat Basal Ganglia. Advances in Experimental Medicine and Biology, 1987, 217, 285-294.	0.8	10
261	Substance P-Containing terminals in synaptic contact with cholinergic neurons in the neostriatum and basal forebrain: a double immunocytochemical study in the rat. Brain Research, 1986, 397, 279-289.	1.1	254
262	Cholecystokinin-immunoreactive boutons in synaptic contact with hippocampal pyramidal neurons that project to the nucleus accumbens. Neuroscience, 1986, 19, 181-192.	1.1	72
263	Relationships between catecholaminergic neurons and cholecystokinin-containing neurons in the caudal part of the dorsomedial medulla oblongata of the rat: light and electron microscopic observations by the â€~mirror technique'. Brain Research, 1986, 370, 343-348.	1.1	19
264	Ultrastructural evidence of dopaminergic input to enkephalinergic neurons in rat neostriatum. Brain Research, 1986, 367, 374-378.	1.1	122
265	Synaptic connections of axo-axonic (chandelier) cells in human epileptic temporal cortex. Neuroscience, 1986, 19, 1179-1186.	1.1	52
266	Acetylcholinesterase Activity in Regions of the Rat Brain Following a Convulsion. Journal of Neurochemistry, 1986, 46, 1789-1793.	2.1	18
267	Stimulation of oil biodegradation by using slow-release fertilizers. Biochemical Society Transactions, 1985, 13, 523-525.	1.6	1
268	Neuropeptide Y-like immunoreactive structures in the rat stomach with special reference to the noradrenaline neuron system. Gastroenterology, 1985, 89, 118-126.	0.6	55
269	Glutamate decarboxylase-immunoreactive structures in the rat neostriatum: A correlated light and electron microscopic study including a combination of Golgi impregnation with immunocytochemistry. Journal of Comparative Neurology, 1985, 237, 1-20.	0.9	218
270	Cholecystokinin-immunoreactive cells form symmetrical synaptic contacts with pyramidal and nonpyramidal neurons in the hippocampus. Journal of Comparative Neurology, 1985, 237, 485-505.	0.9	138

#	Article	IF	CITATIONS
271	A correlated light and electron microscopic study of identified cholinergic basal forebrain neurons that project to the cortex in the rat. Journal of Comparative Neurology, 1985, 239, 176-192.	0.9	126
272	Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study. Journal of Neuroscience, 1985, 5, 603-616.	1.7	327
273	An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. Brain Research, 1985, 331, 172-175.	1.1	515
274	Three dimensional analysis of retinal neuropeptides and amine in the chick. Brain Research Bulletin, 1985, 15, 155-165.	1.4	46
275	CABA axons in synaptic contact with dopamine neurons in the substantia nigra: double immunocytochemistry with biotin-peroxidase and protein A-colloidal gold. Brain Research, 1985, 348, 146-154.	1.1	74
276	Synaptic interaction between catecholaminergic neurons and substance P-immunoreactive axons in the caudal part of the nucleus of the solitary tract of the rat: demonstration by the electron microscopic mirror technique. Brain Research, 1985, 333, 188-192.	1.1	50
277	Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin- immunoreactive material. Journal of Neuroscience, 1984, 4, 2590-2603.	1.7	713
278	Characterization of pallidonigral neurons in the rat by a combination of Golgi impregnation and retrograde transport of horseradish peroxidase: their monosynaptic input from the neostriatum. Journal of Neurocytology, 1984, 13, 593-616.	1.6	33
279	Aspiny neurons and their local axons in the neostriatum of the rat: a correlated light and electron microscopic study of Golgi-impregnated material. Journal of Neurocytology, 1984, 13, 239-265.	1.6	65
280	Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience, 1984, 12, 711-718.	1.1	442
281	The section-Golgi-impregnation procedure—3. Combination of Golgi-impregnation with enzyme histochemistry and electron microscopy to characterize acetylcholinesterase-containing neurons in the rat neostriatum. Neuroscience, 1984, 12, 687-709.	1.1	118
282	Factors influencing the cholinesterases of cerebrospinal fluid in the anaesthetized cat. Neuroscience, 1984, 12, 979-995.	1.1	18
283	Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience, 1984, 13, 1189-1215.	1.1	846
284	ALZHEIMER'S DISEASE AND ACETYLCHOLINESTERASE-CONTAINING NEURONS. Lancet, The, 1984, 323, 513.	6.3	31
285	Growth of central substance P-containing neurons into superior cervical ganglia transplanted in the spinal cord of adult rats. Brain Research, 1984, 324, 134-137.	1.1	5
286	Cholinergic synapses in the rat brain: a correlated light and electron microscopic immunohistochemical study employing a monoclonal antibody against choline acetyltransferase. Brain Research, 1984, 308, 69-76.	1.1	197
287	Localization of substance P-like immunoreactivity in neurons and nerve terminals in the neostriatum of the rat: a correlated light and electron microscopic study. Journal of Neurocytology, 1983, 12, 325-344.	1.6	183
288	A type of aspiny neuron in the rat neostriatum accumulates [3H]?-aminobutyric acid: Combination of golgi-staining, autoradiography, and electron microscopy. Journal of Comparative Neurology, 1983, 213, 121-134.	0.9	197

#	Article	IF	CITATIONS
289	Fine structural studies on a type of somatostatin-immurioreactive neuron and its synaptic connections in the rat neostriatum: A correlated light and electron microscopic study. Journal of Comparative Neurology, 1983, 214, 1-16.	0.9	150
290	Glutamate decarboxylase-immunoreactive terminals of Golgi-impregnated axoaxonic cells and of presumed basket cells in synaptic contact with pyramidal neurons of the cat's visual cortex. Journal of Comparative Neurology, 1983, 221, 263-278.	0.9	324
291	The section-Golgi impregnation procedure. 2. Immunocytochemical demonstration of glutamate decarâ ylase in Golgi-impregnated neurons and in their afferent synaptic boutons in the visual cortex of the cat. Neuroscience, 1983, 9, 475-490.	1.1	128
292	DECREASED CSF ACETYLCHOLINESTERASE ACTIVITY IN ALZHEIMER'S DISEASE. Lancet, The, 1983, 322, 452.	6.3	60
293	Uptake of [3H]taurine into medium-size neurons and into identified striatonigral neurons in the rat neostriatum. Brain Research, 1983, 289, 342-348.	1.1	43
294	A new type of specific interneuron in the monkey hippocampus forming synapses exclusively with the axon initial segments of pyramidal cells. Brain Research, 1983, 259, 137-142.	1.1	255
295	Glutamate decarboxylase immunoreactivity in the hippocampus of the cat: distribution of immunoreactive synaptic terminals with special reference to the axon initial segment of pyramidal neurons. Journal of Neuroscience, 1983, 3, 1450-1468.	1.7	216
296	FETAL CALF SERUM AS CAUSE OF FALSE POSITIVE AMNIOTIC FLUID ACETYLCHOLINESTERASE GEL TESTS. Lancet, The, 1982, 320, 1044.	6.3	9
297	Synaptic connections of substance P-immunoreactive nerve terminals in the substantia nigra of the rat. Cell and Tissue Research, 1982, 223, 469-86.	1.5	90
298	Synaptic connections of enkephalin-immunoreactive nerve terminals in the neostriatum: a correlated light and electron microscopic study. Journal of Neurocytology, 1982, 11, 779-807.	1.6	116
299	Monosynaptic input from the nucleus accumbens-ventral striatum region to retrogradely labelled nigrostriatal neurones. Brain Research, 1981, 217, 245-263.	1.1	200
300	The proportion of neurons in the rat neostriatum that project to the substantia nigra demonstrated using horseradish peroxidase conjugated with wheatgerm agglutinin. Brain Research, 1981, 220, 339-343.	1.1	78
301	A second type of striatonigral neuron: a comparison between retrogradely labelled and golgi-stained neurons at the light and electron microscopic levels. Neuroscience, 1981, 6, 2141-2157.	1.1	113
302	Monosynaptic cortical input and local axon collaterals of identified striatonigral neurons. A light and electron microscopic study using the golgi-peroxidase transport-degeneration procedure. Journal of Comparative Neurology, 1981, 195, 567-584.	0.9	426
303	EARLY ANTENATAL DIAGNOSIS OF EXOMPHALOS. Lancet, The, 1980, 315, 1368-1369.	6.3	35
304	AMNIOTIC-FLUID ACETYLCHOLINESTERASE AND NEURAL-TUBE DEFECTS: PLEA FOR STANDARDISATION. Lancet, The, 1979, 314, 307-308.	6.3	10
305	AMNIOTIC-FLUID ACETYLCHOLINESTERASE AS A POSSIBLE DIAGNOSTIC TEST FOR NEURAL-TUBE DEFECTS IN EARLY PREGNANCY. Lancet, The, 1979, 313, 685-688.	6.3	176
306	An approach to tracing neuron networks in the cerebral cortex and basal ganglia. Combination of golgi staining, retrograde transport of horseradish peroxidase and anterograde degeneration of synaptic boutons in the same material. Neuroscience, 1979, 4, 1805-1852.	1.1	353

#	Article	IF	CITATIONS
307	The effect of chlorpromazine on the concentration of acetylcholinesterase in the cerebrospinal fluid of rabbits. Neuropharmacology, 1979, 18, 127-132.	2.0	36
308	Projection of neostriatal spiny neurons to the substantia nigra. Application of a combined golgi-staining and horse-radish peroxidase transport procedure at both light and electron microscopic levels. Brain Research, 1979, 178, 3-15.	1.1	198
309	The influence of electrical stimulation of certain brain regions on the concentration of acetylcholinesterase in rabbit cerebrospinal fluid. Brain Research, 1979, 177, 445-459.	1.1	66
310	Amniotic-Fluid Acetylcholinesterase as a Possible Diagnostic Test for Neural-Tube Defects in Early Pregnancy. Obstetrical and Gynecological Survey, 1979, 34, 745-746.	0.2	0
311	Intracellular localization of acetylcholinesterase in nerve terminals and capillaries of the rat superior cervical ganglion. Journal of Neurocytology, 1978, 7, 145-154.	1.6	30
312	Separation of Multiple Molecular Forms of Acetylcholinesterase by Using Affinity Chromatography: Isolation of the â€~Secretory' Form. Biochemical Society Transactions, 1978, 6, 648-649.	1.6	6
313	Is acetylcholinesterase secreted from central neurons into the cerebrospinal fluid?. Neuroscience, 1976, 1, 57-IN16.	1.1	150
314	Gel electrophoresis of soluble and insoluble proteins of noradrenergic vesicles from ox splenic nerve: A comparison with proteins of adrenal chromaffin granules. Neuroscience, 1976, 1, 339-IN9.	1.1	36
315	Isoenzymes of soluble and membrane-bound acetylcholinesterase in bovine splanchnic nerve and adrenal medulla. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1975, 191, 245-261.	1.8	76
316	Release of acetylcholinesterase into the perfusate from the ox adrenal gland. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1975, 191, 263-269.	1.8	56
317	A possible structural basis for the extracellular release of acetylcholinesterase. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1975, 191, 271-283.	1.8	80
318	[39] Adrenal chromaffin granules: Isolation and disassembly. Methods in Enzymology, 1974, 31, 379-389.	0.4	76
319	Evidence for the presence of dopamine-?-hydroxylase in both populations of noradrenaline storage vesicles in sympathetic nerve terminals of the rat vas deferens. Journal of Neurochemistry, 1973, 20, 245-248.	2.1	55
320	MECHANISMS INVOLVED IN THE RELEASE OF NORADRENALINE FROM SYMPATHETIC NERVES. British Medical Bulletin, 1973, 29, 123-129.	2.7	124
321	Fundamental Mechanisms in the Release of Catecholamines. , 1972, , 538-617.		64
322	A cytochemical study of the calcium-activated adenosinetriphosphatase in hamster adrenal medulla: its occurrence in the golgi region of chromaffin cells. Histochemie Histochemistry Histochimie, 1972, 29, 16-27.	1.3	17
323	Ruthenium red staining of the hamster adrenal medulla. Histochemie Histochemistry Histochimie, 1972, 32, 213-219.	1.3	10
324	Ultrastructural studies on the adrenal medulla of golden hamster: Origin and fate of secretory granules. Cell and Tissue Research, 1972, 124, 367-386.	1.5	73

#	Article	IF	CITATIONS
325	Phaeochromocytoma and Other Catecholamine-Producing Tumours. , 1972, , 900-933.		11
326	Secretion of proteins (chromogranin A and dopamine β-hydroxylase) from a sympathetic neuron. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1971, 261, 363-370.	2.4	51
327	Summing up: some implications of the neuron as a secreting cell. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1971, 261, 423-437.	2.4	99
328	Membrane-bound enzymes in adrenal medulla: an adenosine triphosphatase characteristic of the Golgi apparatus. Biochemical Journal, 1971, 122, 46P-47P.	3.2	3
329	Membranes of the adrenal medulla. Behaviour of insoluble proteins of chromaffin granules on gel electrophoresis. Biochemical Journal, 1970, 118, 303-310.	3.2	143
330	Subcellular fractionation of splenic nerve: ATP, chromogranin A and dopamine β-hydroxylase in noradrenergic vesicles. Tissue and Cell, 1970, 2, 529-546.	1.0	139
331	Release of dopamine β-hydroxylase and chromogranin A upon stimulation of the splenic nerve. Tissue and Cell, 1970, 2, 547-568.	1.0	176
332	Extracellular release of lysosomal phospholipases from the perfused adrenal gland. Biochemical Journal, 1969, 114, 72P-72P.	3.2	1
333	Lipids of adrenal chromaffin granules: Fatty acid composition of phospholipids, in particular lysolecithin. Naunyn-Schmiedeberg's Archives of Pharmacology, 1968, 261, 379-388.	1.4	29
334	Mechanism of secretion from the adrenal medulla. Naunyn-Schmiedeberg's Archives of Pharmacology, 1968, 259, 219-220.	1.4	1
335	Some properties of soluble proteins from chromaffin granules of different species. Biochemical Pharmacology, 1968, 17, 1553-1556.	2.0	32
336	CATECHOLAMINES IN PHÆOCHROMOCYTOMA. Lancet, The, 1968, 291, 793-795.	6.3	29
337	Lysosomal phospholipases A1 and A2 of bovine adrenal medulla. Biochemical Journal, 1968, 108, 867-874.	3.2	76
338	The storage of hormones. Biochemical Journal, 1968, 109, 17P-19P.	3.2	8
339	Biochemical and morphological studies on catecholamine storage in human phaeochromocytoma. Clinical Science, 1968, 34, 453-65.	1.2	36
340	Acid Phospholipase A in Lysosomes of the Bovine Adrenal Medulla. Biochemical Journal, 1967, 103, 30C-32C.	2.8	30
341	A simple method for the isolation of adrenal chromaffin granules on a large scale. Biochemical Journal, 1967, 103, 480-482.	2.8	429
342	Purification and properties of an acidic protein from chromaffin granules of bovine adrenal medulla. Biochemical Journal, 1967, 103, 483-492.	2.8	325

#	Article	IF	CITATIONS
343	Lipids of the adrenal medulla. Lysolecithin, a characteristic constituent of chromaffin granules. Biochemical Journal, 1967, 104, 545-549.	2.8	152
344	The positional specificity of lysosomal phospholipase A activities. Biochemical Journal, 1967, 105, 38C-40C.	3.2	41
345	SECRETION FROM THE ADRENAL MEDULLA: BIOCHEMICAL EVIDENCE FOR EXOCYTOSIS. British Journal of Pharmacology and Chemotherapy, 1967, 31, 94-104.	1.5	187
346	Secretion of a Chromaffin Granule Protein, Chromogranin, from the Adrenal Gland after Splanchnic Stimulation. Nature, 1967, 215, 58-59.	13.7	505
347	The localization of lysosomal enzymes in chromaffin tissue. Journal of Physiology, 1966, 183, 179-188.	1.3	82
348	The demonstration of lysosomes in the bovine adrenal medulla. Experientia, 1966, 22, 142-144.	1.2	11
349	Acid Nucleases of the Bovine Adrenal Medulla. Nature, 1965, 207, 634-634.	13.7	10
350	Radioprotective Action of Methoxamine. Nature, 1959, 184, 1729-1730.	13.7	9
351	Rat Brain Glutathione and Pyridoxine Deficiency. Nature, 1959, 184, 2028-2029.	13.7	8
352	Oxford Project to Investigate Memory and Ageing (OPTIMA): A Longitudinal Clinicopathological Study		0

352 of Dementia and Normal Ageing. , 0, , 227-227.